Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2019-05-08 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于首次实施回购股份的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the company's first implementation of a share repurchase (buyback) plan. It details the number of shares repurchased, prices, total amount paid, and references prior approvals and disclosures related to the buyback plan. The document does not contain financial statements or detailed financial analysis but focuses on the transaction of the company buying back its own shares. This matches the definition of 'Transaction in Own Shares' (POS). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the correct classification is POS with high confidence.
2019-05-08 Chinese
关于股份回购的进展公告
Transaction in Own Shares Classification · 95% confidence The document is titled as an announcement regarding the progress of a share repurchase (股份回购的进展公告). It references prior approvals and disclosures related to the share buyback plan and states the current status of the repurchase account and that no repurchase operations have yet been conducted. The document is short (920 characters) and serves as a progress update on the company's share repurchase activity. This fits the category of Transaction in Own Shares (POS), which covers announcements about the company's buyback or sale of its own shares. It is not a full financial report or earnings release, nor is it a regulatory filing or a report publication announcement. Therefore, the correct classification is POS with high confidence.
2019-05-08 Chinese
关于2019年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 瑞康医药集团股份有限公司 regarding the expected daily related-party transactions for the year 2019. It details the nature of the transactions, the related parties involved, pricing principles, and includes independent directors' opinions and board meeting resolutions. The document is an announcement of anticipated related-party transactions rather than a financial report or detailed financial statements. It is relatively short (3418 characters) and does not contain comprehensive financial data or analysis. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-04-29 Chinese
独立董事关于对公司累计和当期担保情况的专项说明及独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's cumulative and current guarantees. It references compliance with regulatory notice 证监发[2005]120 and discusses the company's external guarantee activities and approvals by the board and shareholders. The content focuses on governance and compliance related to guarantees rather than financial results or audit opinions. The document length is short (1180 characters) and it is a formal statement by independent directors, which aligns with a Regulatory Filing (RNS) rather than a full Audit Report or Annual Report. It is not a report publication announcement since it contains substantive content, but it is not a financial report or management report either. Therefore, the best fit is Regulatory Filings (RNS).
2019-04-29 Chinese
第三届监事会第十六次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 3rd Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It includes approvals of the 2018 Annual Report and its summary, the 2018 Supervisory Board Work Report, the 2018 Financial Final Accounts and 2019 Budget Report, the 2018 Internal Control Self-Evaluation Report, the 2018 Special Report on the Use of Raised Funds, the 2018 Profit Distribution Proposal, the reappointment of the accounting firm for 2018 audit, 2019 related party transactions forecast, amendments to the Articles of Association, accounting policy changes, and the 2019 Q1 report. The document contains voting results and states that these reports are available on the official disclosure website (cninfo.com.cn). The document itself is a formal announcement of the Supervisory Board's resolutions approving these reports and proposals, not the reports themselves. The document length is 3815 characters, which is relatively short and mainly serves as a meeting resolution announcement. Therefore, it fits best as a Regulatory Filing (RNS) rather than the actual Annual Report (10-K) or Interim Report (IR).
2019-04-29 Chinese
第三届董事会第二十一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 21st meeting of the third board of directors of 瑞康医药集团股份有限公司. It includes approvals of the 2018 annual report and its summary, the 2018 general manager work report, the 2018 board work report, the 2018 financial statements and 2019 budget, internal control reports, profit distribution plan, auditor reappointment, amendments to company articles, and the 2019 Q1 report. The document contains substantive financial data such as revenue, net profit, and budget figures, and it is not merely an announcement of a report being published or attached. The content is consistent with a board meeting resolution document that includes management reports and financial results discussion. However, since it is a board meeting resolution announcement rather than the full annual report or quarterly report itself, and it focuses on board decisions and approvals, the best fitting category is Board/Management Information (MANG). The document is not a full annual report (10-K) or interim report (IR) because it does not contain the full financial statements but rather approvals and summaries. It is not a Regulatory Filing (RNS) because it is a formal board meeting resolution announcement with detailed content. Therefore, the classification is MANG with high confidence.
2019-04-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.